Publication details
Empagliflozin a srdeční selhání
| Title in English | Empagliflozine and Heart Failure |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Hypertenze & kardiovaskulární prevence |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | Empagliflozine; Diabetes mellitus; Heart failure |
| Description | Empagliflozin, a newmember of SGLT2 class, showed significant cardiovascular morbidity and mortality benefit in recently published EMPA-REG OUTCOME trial. The authors summarize all the published clinical and preclinical cardiovascular outcome data of SGLT2 inhibitors. |